UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q/A

(Amendment No. 1)

 

x       QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE QUARTERLY PERIOD ENDED June 30, 2011

 

OR

 

o          TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM            TO            

 

COMMISSION FILE NUMBER 000-19319

 

VERTEX PHARMACEUTICALS INCORPORATED

(Exact name of registrant as specified in its charter)

 

 

(617) 444-6100

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x   No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x  No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o  No x

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Common Stock, par value $0.01 per share		208,087,899
Class		Outstanding at July 29, 2011

 

 

 

Explanatory Note

 

We are filing this Amendment No. 1 to our Quarterly Report on Form 10-Q for the three months ended June 30, 2011, which was originally filed with the Securities and Exchange Commission on August 9, 2011 (the “Quarterly Report”), for the sole purposes of filing, with fewer redactions, two exhibits for which we requested confidential treatment. The Exhibit Index also is being amended to add new officer certifications in accordance with Rule 13a-14(a) of the Exchange Act. This Amendment No. 1 continues to speak as of August 9, 2011, the date of the original filing of the Quarterly Report, and we have not updated the disclosures contained therein to reflect any events that occurred at a later date.

 

2

 

Item 6.  Exhibits

 

						Incorporation by Reference
Exhibit No.		Description		Filed with this Form 10-Q/A		Form or Schedule		Filing Date with SEC		SEC File Number
10.1		License and Collaboration Agreement, dated June 13, 2011, by and between Alios BioPharma, Inc. and Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Switzerland) LLC. †				10-Q		August 9, 2011		000-19319
10.2		Research, Development and Commercialization Agreement, dated May 24, 2004, between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated. † (1)		X
10.3		Amendment No. 5 to Research, Development and Commercialization Agreement, effective as of April 1, 2011, between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated. †				10-Q		August 9, 2011		000-19319
10.4		Lease, dated May 5, 2011, between Fifty Northern Avenue LLC and Vertex Pharmaceuticals Incorporated. †				10-Q		August 9, 2011		000-19319
10.5		Lease, dated May 5, 2011, between Eleven Fan Pier Boulevard LLC and Vertex Pharmaceuticals Incorporated. †				10-Q		August 9, 2011		000-19319
10.6		Amendment No. 2 to Research, Development and Commercialization Agreement, effective as of January 1, 2006, between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated. (2)		X
31.1		Certification of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.				10-Q		August 9, 2011		000-19319
31.2		Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.				10-Q		August 9, 2011		000-19319
31.3		Certification of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.		X
31.4		Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.		X
32.1		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				10-Q		August 9, 2011		000-19319
101.INS		XBRL Instance*				10-Q		August 9, 2011		000-19319
101.SCH		XBRL Taxonomy Extension Schema*				10-Q		August 9, 2011		000-19319
101.CAL		XBRL Taxonomy Extension Calculation*				10-Q		August 9, 2011		000-19319
101.LAB		XBRL Taxonomy Extension Labels*				10-Q		August 9, 2011		000-19319
101.PRE		XBRL Taxonomy Extension Presentation*				10-Q		August 9, 2011		000-19319
101.DEF		XBRL Taxonomy Extension Definition*				10-Q		August 9, 2011		000-19319

 

*                                         Pursuant to applicable securities laws and regulations, we will be deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and will not be subject to liability under any anti-fraud provisions of the federal securities laws with respect to such interactive data files as long as we have made a good faith attempt to comply with the submission requirements and promptly amend the interactive data files after becoming aware that the interactive data files fail to comply with the submission requirements. Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed and otherwise are not subject to liability, except as provided by applicable securities laws and regulations.

 

†                                          Confidential portions of this document have been filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.

 

3

 

(1)          Originally filed as Exhibit 99.2 to Registrant’s Current Report on Form 8-K/A on September 10, 2004.

 

(2)  Originally filed as Exhibit 10.1 to Registrant’s Quarterly Report on Form 10-Q on May 10, 2006.

 

4

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

August 19, 2011		VERTEX PHARMACEUTICALS INCORPORATED
		By:	/s/ IAN F. SMITH
			Ian F. Smith
			Executive Vice President and Chief Financial Officer
			(principal financial officer and
			duly authorized officer)

 

5